A solid reputation.

Novo Nordisk has been dedicated to growth hormone therapy for over 40 years. Today, Norditropin® (somatropin [rDNA origin] injection) helps people in over 80 countries around the world.

  • Novo Nordisk launched its first growth hormone product, called Nanormon®, in 1973.
  • Norditropin® was first approved for use in the United States in 1995 by the Food and Drug Administration (FDA).
  • Norditropin® helps people in over 80 countries around the world.

You’re not the 1st – or even the 1001st.

Your family isn’t the first to deal with a child’s growth hormone-related disorder. Over 43,000 patients have been treated with Norditropin® since 2003.